| Document |
Document Title |
|
JP2004521898A |
Smooth muscle tone modulator compositions and methods of use thereof are provided for the treatment of oesophageal motility disorders and gastro-oesophageal reflux disease. The smooth muscle tone modulators are applied topically to treat...
|
|
JP2004196815A |
To provide an ileal bile acid transport (IBAT) inhibitor useful for treating hyperlipemia.A compound of formula (I) [for example, Rv, Rw, Rx, Ry, R3, and R6 are each H; R1 and R2 are each butyl; R4 is methylthio; R5 is expressed by formu...
|
|
JP2004518699A |
This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.
|
|
JP2004517085A |
The present invention relates to compounds of the formula Iwherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to th...
|
|
JP2004516271A |
A method for treating dyskinesias associated with dopaminergic therapy is described using the a typical antipsychotic agent quetiapine. Also described is the co-administration of quetiapine and a dopaminergic agent for treating Parkinson...
|
|
JP3531954B2 |
PURPOSE: To prepare Diltiazem which is a medicament of angina pectoris by reacting the corresponding benzothiazepine with 2-dimethylaminoethyl chloride in the presence of an alkali metal carbonate in an aromatic solvent and then acetylat...
|
|
JP2004514665A |
Protected N,N'-L-homocystinediyl-bis(6,6-dimethoxy-L-norleucine methyl ester) derivatives (I) are new. The protected N,N'-L-homocystinediyl-bis(6,6-dimethoxy-L-norleucine methyl ester) derivatives are of formula (I). [Image] P1a protecti...
|
|
JP2004508333A |
The present invention relates to methods of treating Attention Deficit Hyperactivity Disorder, Conduct Disorder and related conditions and disorders.
|
|
JP3507124B2 |
PURPOSE: To obtain a benzyidene derivative useful as a nonsteroidal antiinflammatory agent, etc., in a high purity and yield by condensing a specific quinonemethide derivative with a specified nitrogen-containing heterocyclic compound in...
|
|
JP2004505089A |
A process is described for the preparation of compounds with the following formula where the groups are as defined below; in particular, R1 is a substituted amine; said process includes essentially the reaction of pyrrolobenzothiazepin-9...
|
|
JP3497164B2 |
PCT No. PCT/US92/05463 Sec. 371 Date Jun. 26, 1992 Sec. 102(e) Date Jun. 26, 1992 PCT Filed Jun. 26, 1992 PCT Pub. No. WO93/00095 PCT Pub. Date Jan. 7, 1993This invention relates to compounds of the formula: wherein A1 to A5 form an acce...
|
|
JP3487611B2 |
PURPOSE: To obtain new compds. useful as dual inhibitors having inhibitory activity against angiotensin converting enzyme and neutral endopeptidase in the treatment of hypertension, congestive heart failure, hepatocirrhosis, etc. CONSTIT...
|
|
JP2003534230A |
[Chemical 1]
|
|
JP2003533440A |
Vasopeptidase inhibitors, especially omapatrilat, are useful in treating isolated systolic hypertension. The vasopeptidase inhibitor may be used in combination with other pharmaceutically active agents.
|
|
JP3462234B2 |
PURPOSE: To obtain a new heterocyclic compound, having excellent choline esterase inhibiting activity and antidepressant action and useful as a therapeutic or a preventing agent for senile dementia. CONSTITUTION: The compound of formula ...
|
|
JP2003530388A |
A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
|
|
JP2003523337A |
A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hy...
|
|
JP2003519629A |
The invention relates to nonpeptide oligomers of amino acids. The oligomers comprise -(NR'-A-CO)-O- units which represent a nonpeptide, restricted-mimetic inducer of the beta turn in a dipeptide or tripeptide fragment. Said oligomers may...
|
|
JP2003119137A |
To provide a compound and its pharmaceutically permissible salt effective for suppressing the HIV proliferation of affected cell of latency phase and enabling the suppression of the proliferation of virus in the latency phase from the in...
|
|
JP2003513008A |
The present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula (I) in whi...
|
|
JP2003513082A |
The invention is directed to nonpeptide substituted benzodiazepines of Formula I,wherein A, X, Z, Bp, W, n, R1 and R2 are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions inv...
|
|
JP2003500353A |
A method of treating weight in patients, in particular those suffering from psychoses, by administering the antipsychotic agent quetiapine.
|
|
JP2002541248A |
The invention relates to substituted 1,4-benzothiazepine-1,1-dioxide derivatives and their acid addition salts.1,4-Benzothiazepine-1,1-dioxide derivatives of formula 1,wherein R1, R2, R3, and Z have the meanings indicated in the specific...
|
|
JP2002540197A |
Compounds of formula (I) are antibacterial agents wherein: R3 and R4, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atom...
|
|
JP3347331B2 |
The invention provides compounds of formulaas described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptacle salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhib...
|
|
JP3349086B2 |
To provide the subject compound useful as an intermediate for synthesizing medicinal compounds in a high purity and in a high yield by crystallizing the compound from a solution containing the optically active compound, the other optical...
|
|
JP2002536440A |
Novel 1,1-dioxido-1,2-benzothiazepines, derivatives and analogs thereof, pharmaceutical compositions containing them, and their use in medicine, particularly in the prophylaxis and/or treatment of hyperlipidemic diseases, conditions and/...
|
|
JP2002535382A |
Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage...
|
|
JP2002534517A |
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1, 3-thiazolidines, 2-arylimino-2, 3, 4, 5-tetrahydro-1, 3-thiazines, 2-arylimino-1, 3-thiazolidin-4-ones, 2-arylimino-1, 3-thiazolidin-5-ones, and 2-arylimino-1, ...
|
|
JP2002533414A |
The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed inc...
|
|
JP2002241368A |
To provide an excellent neuropeptide Y(NPY) antagonist, i.e., an antifeeding agent, a therapeutic agent for myocardial infarction, a therapeutic agent for angina pectoris and an antihypertensive agent.A compound represented by the formul...
|
|
JP2002527502A |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
|
JP2002526411A |
The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases caused by degeneration of visual recept...
|
|
JP2002518491A |
The present invention relates to compound of formula (I), that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molec...
|
|
JP2002518451A |
Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
|
|
JP2002518481A |
Compounds of formula (I), wherein W is a cyclic group of the type (2); (3); Y is represented by the formula (II); these compounds inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzh...
|
|
JP2002517440A |
Novel multibinding compounds are disclosed. The compounds of this invention comprise 2 - 10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca<++> channel, thereby modulating the b...
|
|
JP3287258B2 |
To obtain 1,5-benzodiazepine derivative, useful as an intermediate for a pharmaceutical compound for angina pectoris, etc., by using a specific new compound as a raw material. This 1,5-benzodiazepine derivative of formula II [ring A and ...
|
|
JP2002514647A |
The present application describes novel substituted aryl hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected N, O, an...
|
|
JP3282998B2 |
To obtain a new compound capable of reducing the concentration of an (ultra) low density lipoprotein cholesterol in plasma or serum and useful for treating and preventing hyperlipemia such as atherosclerosis. This compound is represented...
|
|
JP2002051798A |
To provide a method for searching an agent for stimulating the differentiation of osteoblast, by which the search can be performed in a short time.This method for searching the agent for stimulating the differentiation of the osteoblast,...
|
|
JP3256502B2 |
To screening the subject compound by providing the compound to the first and second cell types, measuring the influence thereof on the receptor activities, and selecting the compound providing the influence only to the first cell type. T...
|
|
JP3252900B2 |
To obtain the subject compound useful, e.g. as a raw material for pharmaceuticals by reacting a racemic trans-3(4-lower alkoxyphenyl)glycidic acid ester with an amine compound in the presence of an enzyme originated from microorganism of...
|
|
JP2002500220A |
The invention is concerned with novel hypolipidemic compounds of formula (I),wherein R1 is H or methyl, and salts, solvates or physiologically functional derivatives thereof, with processes and novel intermediates for their preparation, ...
|
|
JP3242140B2 |
PURPOSE: To obtain a bactericidal compsn. having an improved effect. CONSTITUTION: A new bactericidal compsn. comprising one or more compound(s) selected from specified 6-aryl-2-(2-'-alkynyl)pyridazinones and/or 6-aryl-2-(2'- alkynyl)-4,...
|
|
JP3234190B2 |
To obtain in high yield the subject compound having high purity by reacting a styrene derivative with an asymmetric oxidant obtainable from a chiral ketone compound and an oxidant and to obtain in high productivity and economy the subjec...
|
|
JP3231834B2 |
PURPOSE: To prepare a new compd. excellent in bleachability, oxidizability and disinfecting properties and useful for detergents, peracid salt activators or the like. CONSTITUTION: A compd. of formula I {A is formula II [R1 is H, chlorin...
|
|
JP2001520219A |
A process which allows the re-use of compounds of formula in diltiazem synthesis through a process of conversion to a mixture of enantiomers III-(2R,3R) and III-(2S,3S) is described.
|
|
JP3223317B2 |
To increase the enantiometric purity of the subject compound useful as a raw material, for a coronal vasodilator, or the like, by crystallizing a specific (2R,3S)-3-(4-methoxyphenyl)-glycidic acid ester from a specific solvent. This meth...
|
|
JP2001513565A |
Compounds of structural formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, a...
|
